Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

Main Article Content

RB Warren
A Blauvelt
J Bagel
KA Papp
P Yamauchi
A Armstrong
R Langley
V Vanvoorden
D De Cuyper
L Peterson
N Cross
K Reich

Keywords

Plaque Psoriasis, Bimekizumab, IL-17A, IL-17F, Adalimumab, Biologic, Efficacy, Safety

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Reich K. AAD 2020, NCT03370133

6. Gordon K. AAD 2020, NCT03410992.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 > >>